Acute Respiratory Distress Syndrome (ARDS) Clinical Trial
Official title:
A Parallel-arm, Single Blind Randomised Controlled Trial Comparing 'AIRWAY PRESSURE RELEASE VENTILATION' and 'LOW-TIDAL VOLUME VENTILATION' in Children With Acute Respiratory Distress Syndrome
This study attempts to study a new ventilation mode in children with Acute respiratory
distress syndrome (ARDS). Despite decades of research, no intervention has brought about a
significant decrease in ARDS mortality. Moreover, most of the studies are adult-based and
have been extrapolated to children. Airway pressure release ventilation (APRV) mode is
hypothesized to be superior in terms of lower need for sedation, shorter duration of
mechanical ventilation, etc. It is unique and the first worldwide randomized controlled
trial on APRV mode in children.
We plan to recruit a minimum of 50 children aged (1 month-12 years) in each group. The study
is to be conducted at the Post-Graduate Institute of Medical Education and Research
(PGIMER), Chandigarh between March 2014 to March 2016. This trial would recruit children
with respiratory failure and early ARDS and, randomize them to receive either conventional
ventilation or the APRV mode. Rest of the supportive care has also been protocolized so that
both groups receive treatment as per the existing best practices in every aspect. The
primary outcome being studied is the number of ventilator-free days. The secondary outcomes
include length of PICU stay, hospital stay, organ-failure free days, 28 day & 3 month
survival, biomarkers of lung injury (IL-6, IL-8, Angiopoeitin-2, soluble-ICAM-1, etc),
functional status, Pulmonary function tests, etc. Funding request would be sent to the
Indian Council of Medical Research, New Delhi, India.
Assessing lung biomarkers like Interleukin-6 would assess the role of different modes of
ventilation in acting as triggers for multi-organ dysfunction as well as for worsening lung
injury. This pathbreaking research is likely to open up new avenues upon completion.
Study setting:
15-bedded pediatric intensive care unit (PICU) of a multi-specialty, tertiary referral and
teaching hospital- the Advanced Pediatrics Centre (APC) in Post-Graduate Institute of
Medical Education and Research (PGIMER), Chandigarh, India Study period Recruitment: January
2014 to December 2016 Data Analysis: Jan 2017 to June 2017 Study design An open-labelled,
parallel-arm, efficacy/feasibility randomized controlled trial Ethics approval Ethics
approval has been obtained from the Institute Ethics Committee. The study has been
registered with Clinical Trials Registry - India (CTRI) (ctri.nic.in). Informed consent will
be obtained from the parents/legal guardian and the conversation would be recorded using a
camera (audio-visual documentation of evidence).
Sample size estimation Assuming alpha error of 5% and power of 80% with non-inferiority
limit of 4 days (Standard deviation of VFDs being 8.2 days in the conventional low tidal
volume ventilation group in pilot trial), sample size was calculated to be 52 per group. As
this is a safety and feasibility trial, an interim analysis would be done at 50% enrolment.
Enrolment Parents or legal guardians of children who satisfy the above eligibility criteria
will be invited by the investigator to participate in the study. Parents are free not to
participate, or to withdraw from the study at any point of time. All children, irrespective
of their enrollment in the study, will receive standard pediatric intensive care unit (PICU)
care as per the unit's existing protocol. An information sheet (in Hindi/ English)
furnishing details of the study will be provided to the parents. Given the fact that all
these children are sedated and on mechanical ventilation, obtaining assent would not be
feasible in this study.
Randomization Sequence generation A computer-generated, unstratified, block randomization
with variable block sizes will be performed to determine group allocation. A person not
involved in the study will perform the random number allocation and prepare opaque, sealed
envelopes containing the allocation.
Concealment allocation Each pre-sealed opaque envelope would be opened only after obtaining
a written consent and audio-visual record of the same. As the randomization is done using a
variable block size, and prepared by a statistician not directly involved in the study,
there would be no way of predicting the random allocation, thus minimizing the risk of
allocation bias.
Randomization implementation After parents provide informed consent, randomization would be
done within the next one hour and child initiated on appropriate mode of ventilation. The
supportive care for both the groups, would be as per the attached supplementary protocols
Intervention protocol:
The Airway pressure release ventilation (APRV) intervention protocol has been designed based
on the available APRV literature as of Dec 2013.
Start the child on APRV mode of ventilation with the following settings:
- P HIGH would determine the degree of baseline lung inflation. A rough estimate can be
obtained based on the plateau pressure requirements on the conventional mode of
ventilation. Perform an inspiratory hold to ascertain the plateau pressures:
- If P plateau > 30 cm water, set P HIGH at 30 cm water
- If P plateau < 30 cm water, set P HIGH at or 1-2 cm above the measured P plateau.
- Alternatively, if P plateau cannot be measured, P HIGH can be set according to the
following guide:
PaO2/ FiO2 ratio P High < 250 15-20 < 200 20-25 < 150 25-28
After initiating a particular P HIGH, a clinical assessment of lung volume needs to be
followed with a chest radiograph to determine the degree of lung inflation (similar to
setting of Mean airway pressure in High frequency oscillatory mode of ventilation). The
child's P HIGH is adjusted to maintain optimal lung volume, without clinical or radiological
evidence of hyperinflation: no signs of decreased cardiac output/ hypotension and/or the
level of the diaphragm visible greater than the ninth rib.
- Start at T High of 4 seconds; Titrate T High based on oxygenation status. At least 80
-95% of the total cycle time should be spent in T High.
- Set P Low at Zero cm H2O
- Set T Low so that expiratory flow decreases by 25 % of peak expiratory flow rate
(PEFR); usually 0.1-0.8 seconds. The ratio of T-PEFR to PEFR should be targeted near
75%. This entity needs to be titrated every 2-4 hours and may have to be shortened as
lung injury advances.
- Set Pressure Support at ZERO
- The number of breaths per minute or number of releases is a function of T High and T
Low as depicted below:
Weaning from APRV would also be carried out in a structured, protocolized manner. The
following strategies would be adopted:
1. As child's clinical condition and oxygenation index improves, and Fraction of inspired
oxygen levels are brought down to 0.6, T HIGH is increased in steps of 0.5-2 seconds
till it is 10-12 seconds.
2. P HIGH can be subsequently decreased in steps of 2-3 cm H2O till a value of 12-16 is
reached. Decrease in P HIGH can be carried out earlier if features of hyperinflation
(clinical/radiological) appear at any point.
3. The goal is to reach pressure levels of 12-16 cm H2O and then switch to Continuous
positive airway pressure (CPAP) of 6-8 cm H2O, from which child can be extubated
directly to nasal prong CPAP or gradually tapered off CPAP to Endotracheal-T piece and
subsequently extubated depending on the overall clinical status.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03909854 -
Pragmatic Investigation of Volume Targeted Ventilation-1
|
N/A | |
Recruiting |
NCT02637011 -
Surviving ARDS: The Influence of Quality of Care and Individual Patient Characteristics on Quality of Life
|
N/A | |
Completed |
NCT02288949 -
Stratification of the Acute Respiratory Distress Syndrome
|
||
Recruiting |
NCT02574169 -
Alveolar Recruitment Maneuvers, Intracerebral Hemodynamic and Oxygenation
|
N/A | |
Completed |
NCT04548739 -
Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
|
||
Completed |
NCT05024500 -
Clinical and Functional Outcomes of Critically Ill Patients With COVID-19
|
N/A | |
Terminated |
NCT04511650 -
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
|
Phase 2 | |
Recruiting |
NCT01339533 -
Airway Pressure Release Ventilation (APRV) Versus AC/VC Conventional Ventilation
|
Phase 2 | |
Active, not recruiting |
NCT01274260 -
Trial of Steroids in Pediatric Acute Lung Injury/ARDS
|
Phase 2 | |
Recruiting |
NCT03296059 -
Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates
|
N/A | |
Terminated |
NCT04609865 -
Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia
|
Phase 3 | |
Active, not recruiting |
NCT04009330 -
Clinical Evaluation of a Point of Care (POC) Assay to Identify Phenotypes in the Acute Respiratory Distress Syndrome
|
||
Not yet recruiting |
NCT06127381 -
An Open-label Study of the Safety and Pharmacokinetics of the TGKP
|
Phase 1 | |
Not yet recruiting |
NCT05847517 -
Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN)
|
Phase 3 | |
Completed |
NCT01854424 -
Validation of the Percentage of Alveolar Fibrocyte as Biomarker During ARDS
|
N/A | |
Completed |
NCT03870009 -
Validation of a Semi-automatized Method to Detect Cyclic Hyperinflation on CT-scan in ARDS
|
N/A | |
Completed |
NCT04311697 -
Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
|
Phase 2/Phase 3 | |
Recruiting |
NCT02095444 -
Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection
|
Phase 1/Phase 2 | |
Recruiting |
NCT04460859 -
RecruitmEnt Assessed by eleCtRical Impedance Tomography
|
||
Completed |
NCT01926093 -
Low Dose Lung CT Scan for Quantitative Analysis in ARDS Patients
|
N/A |